227 related articles for article (PubMed ID: 29959534)
1. Combination of APD668, a G protein-coupled receptor 119 agonist with linagliptin, a DPPIV inhibitor, prevents progression of steatohepatitis in a murine model of non-alcoholic steatohepatitis with diabetes.
Bahirat UA; Talwar R; Shenoy RR; Nemmani KVS; Goel RN
Med Mol Morphol; 2019 Mar; 52(1):36-43. PubMed ID: 29959534
[TBL] [Abstract][Full Text] [Related]
2. Co-administration of APD668, a G protein-coupled receptor 119 agonist and linagliptin, a DPPIV inhibitor, prevents progression of steatohepatitis in mice fed on a high trans-fat diet.
Bahirat UA; Shenoy RR; Talwar R; Goel RN; Nemmani KVS
Biochem Biophys Res Commun; 2018 Jan; 495(2):1608-1613. PubMed ID: 29203247
[TBL] [Abstract][Full Text] [Related]
3. APD668, a G protein-coupled receptor 119 agonist improves fat tolerance and attenuates fatty liver in high-trans fat diet induced steatohepatitis model in C57BL/6 mice.
Bahirat UA; Shenoy RR; Goel RN; Nemmani KV
Eur J Pharmacol; 2017 Apr; 801():35-45. PubMed ID: 28274625
[TBL] [Abstract][Full Text] [Related]
4. Gliptins Suppress Inflammatory Macrophage Activation to Mitigate Inflammation, Fibrosis, Oxidative Stress, and Vascular Dysfunction in Models of Nonalcoholic Steatohepatitis and Liver Fibrosis.
Wang X; Hausding M; Weng SY; Kim YO; Steven S; Klein T; Daiber A; Schuppan D
Antioxid Redox Signal; 2018 Jan; 28(2):87-109. PubMed ID: 28635324
[TBL] [Abstract][Full Text] [Related]
5. Empagliflozin (an SGLT2 inhibitor), alone or in combination with linagliptin (a DPP-4 inhibitor), prevents steatohepatitis in a novel mouse model of non-alcoholic steatohepatitis and diabetes.
Jojima T; Tomotsune T; Iijima T; Akimoto K; Suzuki K; Aso Y
Diabetol Metab Syndr; 2016; 8():45. PubMed ID: 27462372
[TBL] [Abstract][Full Text] [Related]
6. Linagliptin alleviates hepatic steatosis and inflammation in a mouse model of non-alcoholic steatohepatitis.
Klein T; Fujii M; Sandel J; Shibazaki Y; Wakamatsu K; Mark M; Yoneyama H
Med Mol Morphol; 2014 Sep; 47(3):137-49. PubMed ID: 24048504
[TBL] [Abstract][Full Text] [Related]
7. INT-767 improves histopathological features in a diet-induced
Roth JD; Feigh M; Veidal SS; Fensholdt LK; Rigbolt KT; Hansen HH; Chen LC; Petitjean M; Friley W; Vrang N; Jelsing J; Young M
World J Gastroenterol; 2018 Jan; 24(2):195-210. PubMed ID: 29375205
[TBL] [Abstract][Full Text] [Related]
8. Role of linagliptin in preventing the pathological progression of hepatic fibrosis in high fat diet and streptozotocin-induced diabetic obese rats.
Aboulmagd YM; El-Bahy AAZ; Menze ET; Azab SS; El-Demerdash E
Eur J Pharmacol; 2020 Aug; 881():173224. PubMed ID: 32454118
[TBL] [Abstract][Full Text] [Related]
9. Dipeptidyl peptidase-4 inhibition prevents nonalcoholic steatohepatitis-associated liver fibrosis and tumor development in mice independently of its anti-diabetic effects.
Kawakubo M; Tanaka M; Ochi K; Watanabe A; Saka-Tanaka M; Kanamori Y; Yoshioka N; Yamashita S; Goto M; Itoh M; Shirakawa I; Kanai S; Suzuki H; Sawada M; Ito A; Ishigami M; Fujishiro M; Arima H; Ogawa Y; Suganami T
Sci Rep; 2020 Jan; 10(1):983. PubMed ID: 31969650
[TBL] [Abstract][Full Text] [Related]
10. Progression of non-alcoholic steatosis to steatohepatitis and fibrosis parallels cumulative accumulation of danger signals that promote inflammation and liver tumors in a high fat-cholesterol-sugar diet model in mice.
Ganz M; Bukong TN; Csak T; Saha B; Park JK; Ambade A; Kodys K; Szabo G
J Transl Med; 2015 Jun; 13():193. PubMed ID: 26077675
[TBL] [Abstract][Full Text] [Related]
11. PARP inhibition protects against alcoholic and non-alcoholic steatohepatitis.
Mukhopadhyay P; Horváth B; Rajesh M; Varga ZV; Gariani K; Ryu D; Cao Z; Holovac E; Park O; Zhou Z; Xu MJ; Wang W; Godlewski G; Paloczi J; Nemeth BT; Persidsky Y; Liaudet L; Haskó G; Bai P; Boulares AH; Auwerx J; Gao B; Pacher P
J Hepatol; 2017 Mar; 66(3):589-600. PubMed ID: 27984176
[TBL] [Abstract][Full Text] [Related]
12. CD44 is a key player in non-alcoholic steatohepatitis.
Patouraux S; Rousseau D; Bonnafous S; Lebeaupin C; Luci C; Canivet CM; Schneck AS; Bertola A; Saint-Paul MC; Iannelli A; Gugenheim J; Anty R; Tran A; Bailly-Maitre B; Gual P
J Hepatol; 2017 Aug; 67(2):328-338. PubMed ID: 28323124
[TBL] [Abstract][Full Text] [Related]
13. Human amnion epithelial cells and their soluble factors reduce liver fibrosis in murine non-alcoholic steatohepatitis.
Kuk N; Hodge A; Sun Y; Correia J; Alhomrani M; Samuel C; Moore G; Lim R; Sievert W
J Gastroenterol Hepatol; 2019 Aug; 34(8):1441-1449. PubMed ID: 30821873
[TBL] [Abstract][Full Text] [Related]
14. The pan-caspase inhibitor Emricasan (IDN-6556) decreases liver injury and fibrosis in a murine model of non-alcoholic steatohepatitis.
Barreyro FJ; Holod S; Finocchietto PV; Camino AM; Aquino JB; Avagnina A; Carreras MC; Poderoso JJ; Gores GJ
Liver Int; 2015 Mar; 35(3):953-66. PubMed ID: 24750664
[TBL] [Abstract][Full Text] [Related]
15. Necroptosis is a key pathogenic event in human and experimental murine models of non-alcoholic steatohepatitis.
Afonso MB; Rodrigues PM; Carvalho T; Caridade M; Borralho P; Cortez-Pinto H; Castro RE; Rodrigues CM
Clin Sci (Lond); 2015 Oct; 129(8):721-39. PubMed ID: 26201023
[TBL] [Abstract][Full Text] [Related]
16. Metabolic and hepatic effects of liraglutide, obeticholic acid and elafibranor in diet-induced obese mouse models of biopsy-confirmed nonalcoholic steatohepatitis.
Tølbøl KS; Kristiansen MN; Hansen HH; Veidal SS; Rigbolt KT; Gillum MP; Jelsing J; Vrang N; Feigh M
World J Gastroenterol; 2018 Jan; 24(2):179-194. PubMed ID: 29375204
[TBL] [Abstract][Full Text] [Related]
17. Gemcabene downregulates inflammatory, lipid-altering and cell-signaling genes in the STAM™ model of NASH.
Oniciu DC; Hashiguchi T; Shibazaki Y; Bisgaier CL
PLoS One; 2018; 13(5):e0194568. PubMed ID: 29847555
[TBL] [Abstract][Full Text] [Related]
18. Myeloid-specific IRE1alpha deletion reduces tumour development in a diabetic, non-alcoholic steatohepatitis-induced hepatocellular carcinoma mouse model.
Van Campenhout S; Tilleman L; Lefere S; Vandierendonck A; Raevens S; Verhelst X; Geerts A; Van Nieuwerburgh F; Van Vlierberghe H; Devisscher L
Metabolism; 2020 Jun; 107():154220. PubMed ID: 32243868
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic effects of the dipeptidyl peptidase-IV inhibitor, sitagliptin, on non-alcoholic steatohepatitis in FLS-ob/ob male mice.
Onoyama T; Koda M; Okamoto T; Kishina M; Matono T; Sugihara T; Murawaki Y
Mol Med Rep; 2015 Nov; 12(5):6895-902. PubMed ID: 26397061
[TBL] [Abstract][Full Text] [Related]
20. Adipose tissue-derived stem cells prevent fibrosis in murine steatohepatitis by suppressing IL-17-mediated inflammation.
Yamato M; Sakai Y; Mochida H; Kawaguchi K; Takamura M; Usui S; Seki A; Mizukoshi E; Yamashita T; Yamashita T; Ishida K; Nasti A; Tuyen HTB; Komura T; Yoshida K; Wada T; Honda M; Kaneko S
J Gastroenterol Hepatol; 2019 Aug; 34(8):1432-1440. PubMed ID: 30828861
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
